BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ohri N, Dawson LA, Krishnan S, Seong J, Cheng JC, Sarin SK, Kinkhabwala M, Ahmed MM, Vikram B, Coleman CN, Guha C. Radiotherapy for Hepatocellular Carcinoma: New Indications and Directions for Future Study. J Natl Cancer Inst. 2016;108. [PMID: 27377923 DOI: 10.1093/jnci/djw133] [Cited by in Crossref: 52] [Cited by in F6Publishing: 55] [Article Influence: 8.7] [Reference Citation Analysis]
Number Citing Articles
1 Paturel A, Hall J, Chemin I. Poly(ADP-Ribose) Polymerase Inhibition as a Promising Approach for Hepatocellular Carcinoma Therapy. Cancers (Basel) 2022;14:3806. [PMID: 35954469 DOI: 10.3390/cancers14153806] [Reference Citation Analysis]
2 Wu Q, Chen Y, Du S, Hu Y, Yang P, Zeng Z. Early complete tumor response as a survival predictor in hepatocellular carcinoma patients receiving stereotactic body radiation therapy. Clinical and Translational Radiation Oncology 2022. [DOI: 10.1016/j.ctro.2022.03.010] [Reference Citation Analysis]
3 Su K, Gu T, Xu K, Wang J, Liao H, Li X, Wen L, Song Y, Zhong J, He B, Liu X, He J, Liu Y, Li Q, Feng X, Chen S, Yang B, Huang W, Jin H, Luo X, Hu T, Chen J, Wu Z, Lu S, Zhang J, Rao M, Xie Y, Wang J, Zhu X, Chen L, Li B, Su S, Yang X, Wang J, Zeng H, Wang P, Yan M, Chen X, He K, Han Y. Gamma knife radiosurgery versus transcatheter arterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a propensity score matching study. Hepatol Int 2022. [PMID: 35729469 DOI: 10.1007/s12072-022-10339-2] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Qian Y, Gong L, Li S, Mao K, Li X, Liao G. Case Report: Radiotherapy Plus Immunotherapy and Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma With a Right Atrium and Inferior Vena Cava Tumor Thrombus. Front Oncol 2022;12:879454. [DOI: 10.3389/fonc.2022.879454] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 阙 克. Research Progress of PARP1 in Hepatocellular Carcinoma. ACM 2022;12:6893-6899. [DOI: 10.12677/acm.2022.127994] [Reference Citation Analysis]
6 Trotovšek B, Djokić M, Čemažar M, Serša G. New era of electrochemotherapy in treatment of liver tumors in conjunction with immunotherapies. World J Gastroenterol 2021; 27(48): 8216-8226 [DOI: 10.3748/wjg.v27.i48.8216] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
7 Sun N, Zhang J, Li B, Li A, Lv M, Zhang C. Favorable response to multimodal treatment in hepatocellular carcinoma with inferior vena cava and right atrial tumor thrombus and left adrenal gland metastasis: A case report and literature review. Medicine (Baltimore) 2021;100:e27987. [PMID: 34889243 DOI: 10.1097/MD.0000000000027987] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
8 Li L, Li Y, Zou H. A novel role for apatinib in enhancing radiosensitivity in non-small cell lung cancer cells by suppressing the AKT and ERK pathways. PeerJ 2021;9:e12356. [PMID: 34760374 DOI: 10.7717/peerj.12356] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Liu HT, Jiang MJ, Deng ZJ, Li L, Huang JL, Liu ZX, Li LQ, Zhong JH. Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Progresses and Challenges. Front Oncol 2021;11:737497. [PMID: 34745958 DOI: 10.3389/fonc.2021.737497] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
10 Sørensen M, Fode MM, Petersen JB, Holt MI, Høyer M. Effect of stereotactic body radiotherapy on regional metabolic liver function investigated in patients by dynamic [18F]FDGal PET/CT. Radiat Oncol 2021;16:192. [PMID: 34598730 DOI: 10.1186/s13014-021-01909-z] [Reference Citation Analysis]
11 Hassan SA, Ali AAH, Sohn D, Flögel U, Jänicke RU, Korf HW, von Gall C. Does timing matter in radiotherapy of hepatocellular carcinoma? An experimental study in mice. Cancer Med 2021;10:7712-25. [PMID: 34545699 DOI: 10.1002/cam4.4277] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
12 Su TH, Hsu SJ, Kao JH. Paradigm shift in the treatment options of hepatocellular carcinoma. Liver Int 2021. [PMID: 34515412 DOI: 10.1111/liv.15052] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
13 Heller M, Parikh ND, Fidelman N, Owen D. Frontiers of therapy for hepatocellular carcinoma. Abdom Radiol (NY) 2021;46:3648-59. [PMID: 33837453 DOI: 10.1007/s00261-021-03065-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
14 Gkika E, Schimek-Jasch T, Kremp S, Lenz S, Stockinger M, Schaefer-Schuler A, Mix M, Küsters A, Tosch M, Hehr T, Eschmann SM, Bultel YP, Hass P, Fleckenstein J, Thieme AH, Dieckmann K, Miederer M, Holl G, Rischke HC, Adebahr S, König J, Binder H, Grosu AL, Nestle U. Impact of radiotherapy protocol adherence in NSCLC patients treated with concurrent chemoradiation: RTQA results of the PET-Plan trial. Radiother Oncol 2021;163:32-8. [PMID: 34311004 DOI: 10.1016/j.radonc.2021.07.017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
15 Chen LC, Lin HY, Hung SK, Chiou WY, Lee MS. Role of modern radiotherapy in managing patients with hepatocellular carcinoma. World J Gastroenterol 2021; 27(20): 2434-2457 [PMID: 34092968 DOI: 10.3748/wjg.v27.i20.2434] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
16 Brasse D, Burckel H, Marchand P, Rousseau M, Ouadi A, Vanstalle M, Finck C, Laquerriere P, Boisson F. Comparison of the [18F]-FDG and [18F]-FLT PET Tracers in the Evaluation of the Preclinical Proton Therapy Response in Hepatocellular Carcinoma. Mol Imaging Biol 2021;23:724-32. [PMID: 33847900 DOI: 10.1007/s11307-021-01602-3] [Reference Citation Analysis]
17 Yang J, Liang H, Hu K, Xiong Z, Cao M, Zhong Z, Yao Z, Deng M. The effects of several postoperative adjuvant therapies for hepatocellular carcinoma patients with microvascular invasion after curative resection: a systematic review and meta-analysis. Cancer Cell Int 2021;21:92. [PMID: 33549093 DOI: 10.1186/s12935-021-01790-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
18 Zhou WX, Chen C, Liu XQ, Li Y, Kong LY, Luo JG. Synthesis and biological evaluation of novel withangulatin A derivatives as potential anticancer agents. Bioorg Chem 2021;108:104690. [PMID: 33592485 DOI: 10.1016/j.bioorg.2021.104690] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
19 Llovet JM, De Baere T, Kulik L, Haber PK, Greten TF, Meyer T, Lencioni R. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2021;18:293-313. [PMID: 33510460 DOI: 10.1038/s41575-020-00395-0] [Cited by in Crossref: 135] [Cited by in F6Publishing: 149] [Article Influence: 135.0] [Reference Citation Analysis]
20 Zhou J, Sun H, Wang Z, Cong W, Wang J, Zeng M, Zhou W, Bie P, Liu L, Wen T, Han G, Wang M, Liu R, Lu L, Ren Z, Chen M, Zeng Z, Liang P, Liang C, Chen M, Yan F, Wang W, Ji Y, Yun J, Cai D, Chen Y, Cheng W, Cheng S, Dai C, Guo W, Hua B, Huang X, Jia W, Li Y, Li Y, Liang J, Liu T, Lv G, Mao Y, Peng T, Ren W, Shi H, Shi G, Tao K, Wang W, Wang X, Wang Z, Xiang B, Xing B, Xu J, Yang J, Yang J, Yang Y, Yang Y, Ye S, Yin Z, Zhang B, Zhang B, Zhang L, Zhang S, Zhang T, Zhao Y, Zheng H, Zhu J, Zhu K, Liu R, Shi Y, Xiao Y, Dai Z, Teng G, Cai J, Wang W, Cai X, Li Q, Shen F, Qin S, Dong J, Fan J. Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition). Liver Cancer 2020;9:682-720. [PMID: 33442540 DOI: 10.1159/000509424] [Cited by in Crossref: 150] [Cited by in F6Publishing: 164] [Article Influence: 75.0] [Reference Citation Analysis]
21 Gerossier L, Dubois A, Paturel A, Fares N, Cohen D, Merle P, Lachuer J, Wierinckx A, Saintigny P, Bancel B, Selves J, Schnitzler A, Ouine B, Cartier A, de Koning L, Puard V, Bieche I, Hernandez-Vargas H, Hall J, Chemin I. PARP inhibitors and radiation potentiate liver cell death in vitro. Do hepatocellular carcinomas have an achilles' heel? Clin Res Hepatol Gastroenterol 2020;:101553. [PMID: 33183998 DOI: 10.1016/j.clinre.2020.09.014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
22 Haffez H, Taha H, Rabie MA, Awad SM, Zohny YM. Synthesis, biological evaluation and molecular docking studies of novel thiopyrimidine analogue as apoptotic agent with potential anticancer activity. Bioorganic Chemistry 2020;104:104249. [DOI: 10.1016/j.bioorg.2020.104249] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
23 Lee YH, Tai D, Yip C, Choo SP, Chew V. Combinational Immunotherapy for Hepatocellular Carcinoma: Radiotherapy, Immune Checkpoint Blockade and Beyond. Front Immunol 2020;11:568759. [PMID: 33117354 DOI: 10.3389/fimmu.2020.568759] [Cited by in Crossref: 44] [Cited by in F6Publishing: 47] [Article Influence: 22.0] [Reference Citation Analysis]
24 Shin KI, Jang BK, Kim JH, Hwang JS. Huge Hepatocellular Carcinoma Exhibiting a Complete Response after Stereotactic Body Radiation Therapy. J Liver Cancer 2020;20:167-172. [DOI: 10.17998/jlc.20.2.167] [Reference Citation Analysis]
25 Kibe Y, Takeda A, Tsurugai Y, Eriguchi T. Local control by salvage stereotactic body radiotherapy for recurrent/residual hepatocellular carcinoma after other local therapies. Acta Oncol 2020;59:888-94. [PMID: 32216593 DOI: 10.1080/0284186X.2020.1741679] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
26 Sheth N, Osborn V, Lee A, Schreiber D. Stereotactic Ablative Radiotherapy Fractionation for Hepatocellular Carcinoma in the United States. Cureus. 2020;12:e8675. [PMID: 32699675 DOI: 10.7759/cureus.8675] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
27 Smith WH, Ru M, Mcgee HM, Sung M, Rosenzweig KE, Buckstein M. Safety of nivolumab in combination with prior or concurrent radiation therapy in hepatocellular carcinoma. J Radiat Oncol 2020;9:45-52. [DOI: 10.1007/s13566-020-00419-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
28 Andrade FO, Furtado KS, Heidor R, Sandri S, Hebeda CB, Miranda MLP, Fernandes LHG, Yamamoto RC, Horst MA, Farsky SHP, Moreno FS. Antiangiogenic effects of the chemopreventive agent tributyrin, a butyric acid prodrug, during the promotion phase of hepatocarcinogenesis. Carcinogenesis 2019;40:979-88. [PMID: 30590392 DOI: 10.1093/carcin/bgy190] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
29 Fan M, Chen S, Weng Y, Li X, Jiang Y, Wang X, Bie M, An L, Zhang M, Chen B, Huang G, Wu J, Zhu M, Shi Q. Ciprofloxacin promotes polarization of CD86+CD206‑ macrophages to suppress liver cancer. Oncol Rep 2020;44:91-102. [PMID: 32377744 DOI: 10.3892/or.2020.7602] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
30 Durand-Labrunie J, Baumann AS, Ayav A, Laurent V, Boleslawski E, Cattan S, Bogart E, Le Deley MC, Steen V, Lacornerie T, Peiffert D, Mirabel X. Curative Irradiation Treatment of Hepatocellular Carcinoma: A Multicenter Phase 2 Trial. Int J Radiat Oncol Biol Phys. 2020;107:116-125. [PMID: 32001057 DOI: 10.1016/j.ijrobp.2019.12.004] [Cited by in Crossref: 33] [Cited by in F6Publishing: 37] [Article Influence: 16.5] [Reference Citation Analysis]
31 Dobrzycka M, Spychalski P, Rostkowska O, Wilczyński M, Kobiela P, Grąt M, Dell'Acqua V, Høyer M, Jereczek-Fossa BA. Stereotactic body radiation therapy for early-stage hepatocellular carcinoma - a systematic review on outcome. Acta Oncol 2019;58:1706-13. [PMID: 31464155 DOI: 10.1080/0284186X.2019.1657942] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
32 Liao J, Jin H, Li S, Xu L, Peng Z, Wei G, Long J, Guo Y, Kuang M, Zhou Q, Peng S. Apatinib potentiates irradiation effect via suppressing PI3K/AKT signaling pathway in hepatocellular carcinoma. J Exp Clin Cancer Res 2019;38:454. [PMID: 31694662 DOI: 10.1186/s13046-019-1419-1] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
33 Sayan M, Yegya-Raman N, Greco SH, Gui B, Zhang A, Chundury A, Grandhi MS, Hochster HS, Kennedy TJ, Langan RC, Malhotra U, Rustgi VK, Shah MM, Spencer KR, Carpizo DR, Nosher JL, Jabbour SK. Rethinking the Role of Radiation Therapy in the Treatment of Unresectable Hepatocellular Carcinoma: A Data Driven Treatment Algorithm for Optimizing Outcomes. Front Oncol 2019;9:345. [PMID: 31275846 DOI: 10.3389/fonc.2019.00345] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
34 Byun HK, Kim HJ, Im YR, Kim DY, Han K, Seong J. Dose escalation by intensity modulated radiotherapy in liver-directed concurrent chemoradiotherapy for locally advanced BCLC stage C hepatocellular carcinoma. Radiotherapy and Oncology 2019;133:1-8. [DOI: 10.1016/j.radonc.2018.12.025] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
35 Lin Q, Huang X, Zhong C, Luo T, Zeng X, Chen S. Improved survival with radiotherapy in hepatocellular carcinoma with major vascular invasion: A propensity-matched analysis of Surveillance, Epidemiology, and End Results database. Cancer Med 2019;8:515-26. [PMID: 30656831 DOI: 10.1002/cam4.1937] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
36 Dar AR, McKillop I, Vickress J, Lock M, Yartsev S. Prognostic Significance of Tumor Location for Liver Cancer Radiotherapy. Cureus 2018;10:e3714. [PMID: 30788203 DOI: 10.7759/cureus.3714] [Reference Citation Analysis]
37 Baumann BC, Wei J, Plastaras JP, Lukens JN, Damjanov N, Hoteit M, Hsu C, Levine M, Mondschein J, Nadolski G, Olthoff K, Reiss KA, Rosen M, Siegelman E, Metz JM, Ben-Josef E. Stereotactic Body Radiation Therapy (SBRT) for Hepatocellular Carcinoma: High Rates of Local Control With Low Toxicity. Am J Clin Oncol 2018;41:1118-24. [PMID: 29553972 DOI: 10.1097/COC.0000000000000435] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 4.8] [Reference Citation Analysis]
38 Toesca DAS, Ibragimov B, Koong AJ, Xing L, Koong AC, Chang DT. Strategies for prediction and mitigation of radiation-induced liver toxicity. J Radiat Res 2018;59:i40-9. [PMID: 29432550 DOI: 10.1093/jrr/rrx104] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 4.8] [Reference Citation Analysis]
39 Chung YK, Hwang S, Ko GY, Yoon SM. Long-term complete response after transcatheter arterial chemoembolization and stereotactic body radiation therapy in a patient with hepatocellular carcinoma at the caudate lobe. Ann Hepatobiliary Pancreat Surg 2018;22:274-81. [PMID: 30215050 DOI: 10.14701/ahbps.2018.22.3.274] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
40 Boda-Heggemann J, Gkika E, Andratschke N, Blanck O, Guckenberger M, Lohr F, Brunner TB. Correspondence on Rajyaguru et al. J Clin Oncol 2018;36:2561-2. [PMID: 29945524 DOI: 10.1200/JCO.2018.78.1542] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
41 Choi C, Son A, Lee HS, Lee YJ, Park HC. Radiosensitization by Marine Sponge Agelas sp. Extracts in Hepatocellular Carcinoma Cells with Autophagy Induction. Sci Rep 2018;8:6317. [PMID: 29679028 DOI: 10.1038/s41598-018-24745-w] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
42 Jeong Y, Jung J, Cho B, Kwak J, Jeong C, Kim JH, Park JH, Kim SY, Shim JH, Kim KM, Lim YS, Lee HC, Yoon SM. Stereotactic body radiation therapy using a respiratory-gated volumetric-modulated arc therapy technique for small hepatocellular carcinoma. BMC Cancer. 2018;18:416. [PMID: 29653562 DOI: 10.1186/s12885-018-4340-7] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 6.3] [Reference Citation Analysis]
43 Rim CH, Kim CY, Yang DS, Yoon WS. External beam radiation therapy to hepatocellular carcinoma involving inferior vena cava and/or right atrium: A meta-analysis and systemic review. Radiother Oncol. 2018;129:123-129. [PMID: 29606524 DOI: 10.1016/j.radonc.2018.02.030] [Cited by in Crossref: 29] [Cited by in F6Publishing: 36] [Article Influence: 7.3] [Reference Citation Analysis]
44 Venkatesulu BP, Krishnan S. Radiosensitization by inhibiting DNA repair: Turning the spotlight on homologous recombination. Hepatology 2018;67:470-2. [PMID: 28921592 DOI: 10.1002/hep.29526] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
45 Rajyaguru DJ, Borgert AJ, Smith AL, Thomes RM, Conway PD, Halfdanarson TR, Truty MJ, Kurup AN, Go RS. Radiofrequency Ablation Versus Stereotactic Body Radiotherapy for Localized Hepatocellular Carcinoma in Nonsurgically Managed Patients: Analysis of the National Cancer Database. J Clin Oncol. 2018;36:600-608. [PMID: 29328861 DOI: 10.1200/jco.2017.75.3228] [Cited by in Crossref: 110] [Cited by in F6Publishing: 125] [Article Influence: 27.5] [Reference Citation Analysis]
46 Munoz-schuffenegger P, Ng S, Dawson LA. Radiation-Induced Liver Toxicity. Seminars in Radiation Oncology 2017;27:350-7. [DOI: 10.1016/j.semradonc.2017.04.002] [Cited by in Crossref: 45] [Cited by in F6Publishing: 48] [Article Influence: 9.0] [Reference Citation Analysis]
47 Zhong JH, Peng NF, You XM, Ma L, Xiang X, Wang YY, Gong WF, Wu FX, Xiang BD, Li LQ. Tumor stage and primary treatment of hepatocellular carcinoma at a large tertiary hospital in China: A real-world study. Oncotarget 2017;8:18296-302. [PMID: 28407686 DOI: 10.18632/oncotarget.15433] [Cited by in Crossref: 31] [Cited by in F6Publishing: 40] [Article Influence: 6.2] [Reference Citation Analysis]
48 Bae SH, Jang WI, Park HC. Intensity-modulated radiotherapy for hepatocellular carcinoma: dosimetric and clinical results. Oncotarget. 2017;8:59965-59976. [PMID: 28938697 DOI: 10.18632/oncotarget.19219] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
49 Lee J, Lee JH, Yoon H, Lee HJ, Jeon H, Nam J. Extraordinary radiation super-sensitivity accompanying with sorafenib combination therapy: what lies beneath? Radiat Oncol J 2017;35:185-8. [PMID: 28712281 DOI: 10.3857/roj.2017.00262] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
50 Lock MI, Klein J, Chung HT, Herman JM, Kim EY, Small W, Mayr NA, Lo SS. Strategies to tackle the challenges of external beam radiotherapy for liver tumors. World J Hepatol 2017; 9(14): 645-656 [PMID: 28588749 DOI: 10.4254/wjh.v9.i14.645] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
51 Xiang X, Zhong JH, Wang YY, You XM, Ma L, Xiang BD, Li LQ. Distribution of tumor stage and initial treatment modality in patients with primary hepatocellular carcinoma. Clin Transl Oncol 2017;19:891-7. [PMID: 28160206 DOI: 10.1007/s12094-017-1621-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]